Rigel Pharmaceuticals (RIGL) 4.88 $RIGL Traders Get

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 11:33 AM

Rigel Pharmaceuticals (RIGL) 4.88 $RIGL

Traders Get Bullish on Shares of Rigel Pharmaceuticals, Shares Up 12.5% (RIGL)
Comtex SmarTrend(R) - Fri Apr 24, 10:17AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 12.5% to $4.87 on 2.0x average daily volume. Thus far today, Rigel Pharmaceuticals has traded 1.5 million shares, vs. average volume of 764,000 shares per day. The stock has outperformed the Dow (12.5% to the Dow's 0.0%) and outperformed the S&P 500 (12.5% to the S&P's 0.2%) during today's trading.
RIGL: 4.88 (+0.55)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:39PM CDT

MXIM: 32.78 (-1.96), AMZN: 445.10 (+55.11), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), UBNT: 31.29 (-0.14), AWAY: 27.18 (-4.99), ALGN: 59.18 (+3.17), ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52), RIGL: 4.88 (+0.55)

The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners
RIGL: 4.88 (+0.55), ARP: 9.20 (+0.04), EXEL: 3.08 (-0.02)

3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 10:57AM CDT
When you combine a momentum strategy with small-cap stocks, the likelihood of gains is exponential.
RIGL: 4.88 (+0.55), EXEL: 3.08 (-0.02), ARP: 9.20 (+0.04)

Therapy Focus - Beyond Blood Pressure Control For IgA Nephropathy
EP Vantage - Seeking Alpha - Thu Apr 16, 3:54PM CDT
Phase II data from the Swedish group Pharmalink in the autoimmune disorder IgA nephropathy has shone a light on a rare, little-known condition that has no disease-modifying treatments. Tight blood pressure control to minimise the damage from the...
CCXI: 7.62 (-0.27), RIGL: 4.88 (+0.55)

BUYINS.NET: OTIV, JKD, BR, FLO, AIN, RIGL Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Apr 10, 6:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of On Track Innovations Ltd (NASDAQ:OTIV), iShares Morningstar Large Core Index Fund (NYSE:JKD), Big Rock Brewery Inc (NYSE:BR), Flowers Foods Inc (NYSE:FLO), Albany International Corp (NYSE:AIN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AIN: 40.49 (unch), BR: 54.58 (+0.71), OTIV: 1.50 (-0.10), RIGL: 4.88 (+0.55), FLO: 22.31 (-0.20), JKD: 124.24 (+0.71)

Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:07AM CDT
Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue?
RIGL: 4.88 (+0.55)

Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT

CRMD: 8.61 (-0.22), ADXS: 23.34 (-0.27), CYTX: 0.99 (+0.01), CNDO: 3.97 (-0.14), AMRN: 2.33 (-0.10), AVEO: 1.92 (-0.08), NVGN: 6.54 (-0.01), AXN: 1.71 (+0.02), NYMX: 1.39 (-0.05), DRRX: 2.11 (-0.46), RIGL: 4.88 (+0.55), CAPN: 6.87 (+0.01)

Technical Report on Biotech Stocks - Athersys, Dyax Corp., Rigel Pharma, Regeneron Pharma, and BioCryst Pharma
PR Newswire - Mon Apr 06, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BCRX: 10.35 (-0.18), ATHX: 1.29 (-0.03), RIGL: 4.88 (+0.55), REGN: 480.09 (+0.01), DYAX: 27.44 (-0.85)

Rigel Pharmaceuticals (RIGL) Looks Good: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 7:30AM CDT
Rigel Pharmaceuticals, Inc. (RIGL) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
FLML: 15.88 (+0.02), RIGL: 4.88 (+0.55)

Why Rigel Pharmaceuticals Shares Surged Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Rigel Pharmaceuticals ...
RIGL: 4.88 (+0.55)

Rigel Pharmaceuticals Up 10.3%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Tue Mar 31, 11:46AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 10.3% to $3.70 on 1.2x average daily volume. Rigel Pharmaceuticals has traded 1.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.3% to the Dow's -0.5%) and outperformed the S&P 500 (10.3% to the S&P's -0.4%) during today's trading.
RIGL: 4.88 (+0.55)

Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 5.20 (+0.31), PFE: 35.27 (-0.09), AZN: 71.79 (-1.34), ABBV: 66.07 (+1.82), RIGL: 4.88 (+0.55), NVS: 104.28 (-1.22)

Should Rigel Pharmaceuticals (RIGL) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:53AM CDT
Rigel Pharmaceuticals is one such company that looks well positioned for a solid gain, but has been overlooked by investors
RIGL: 4.88 (+0.55)

Why Rigel Pharmaceuticals (RIGL) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:53AM CDT
Rigel Pharmaceuticals in the health care space is seeing solid activity on the earnings estimate revision front
RIGL: 4.88 (+0.55)

Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.32 (-0.14), NWBO: 8.47 (-0.15), ZIOP: 10.81 (-0.39), PCYC: 256.59 (-0.51), CVM: 1.04 (+0.15), PFE: 35.27 (-0.09), CLDX: 30.10 (+0.19), IMGN: 9.96 (-0.29), BMY: 65.80 (-0.20), RIGL: 4.88 (+0.55), INO: 10.35 (-0.25), KITE: 60.58 (-0.35), LH: 126.93 (+0.55), ABBV: 66.07 (+1.82), PBYI: 222.10 (-6.35)

Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:10AM CST
Rigel Pharmaceuticals, Inc.'s (RIGL) fourth-quarter 2014 loss of 25 cents per share was in line with the Zacks Consensus Estimate.
AZN: 71.79 (-1.34), BMY: 65.80 (-0.20), THRX: 17.92 (+0.46), RIGL: 4.88 (+0.55)

Rigel Pharma ups revenues 48% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:14AM CST

RIGL: 4.88 (+0.55)

Rigel reports 4Q loss
Automated Insights - Tue Mar 03, 6:54AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $22.3 million in its fourth quarter.
RIGL: 4.88 (+0.55)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKS Lawsuit Deadline: Investors Must Act by Nov 3, 2026

Clock's Ticking for DICK'S Investors If you've got money tied up in DICK'S Sporting Goods—bought between September 8, 2025, and August 24, 2026—listen up. There's a class action lawsuit aiming to recover some of what might've slipped through your fingers. Come November 3, 2026, the door slams shut on your chance to get involved. What's the Beef? Apparently, DICK'S had...

Fashion and Philanthropy Unite at UBCF Kick-off Party

Exclusivity and Dedication Mix at UBCF Event When fashion and philanthropy get together, you better believe it's more than just a pleasant evening. The Frederick Anderson Collection is hosting a swanky cocktail reception, kicking off the United Breast Cancer Foundation's (UBCF) highly-anticipated Think Pink Gala, and it's shaping up to be a unique affair wrapped in...

Duolingo Investors Must Weigh Legal Options Now

Pressure Mounts on Duolingo Amid Legal Turmoil Well, here's a riddle solved with a lawsuit: when an app's growth hits the brakes, the lawyers seem to get moving fast. It seems like Duolingo, Inc. (NasdaqGS: DUOL) is learning a harsh lesson—not exactly in Spanish or French, but in the courtroom. They've been slapped with a securities class action, and it ain't looking...

Main Street Merger Faces Scrutiny: What It Means for Shareholders

Under the Radar, but Not for Long Ah, mergers—those grand gestures in corporate America that promise growth, synergy, and shareholder value. But not every deal is a head-turner; some fly under the radar until someone grabs the magnifying glass. And that's exactly what's happening with Main Street Financial Services Corp.'s (OTC: MSWV) proposed merger with First...

Bass Angler Matt Robertson Reels in Record $1.25M Prize

A New Era for Bass Fishing Payouts Who would have thought we'd see the day when bass fishing turned out to be as lucrative as a Wall Street handshake? But here we are, with Matt Robertson hauling in a whopping $1.25 million prize at World Bass Enterprises' first "The Champions" Tournament. We're not talking chump change here—this is the real deal in a sport often...

Redtail Tech Faces California Labor Code Allegations

Redtail Technology Caught in Legal Crosshairs The legal arena is heating up as Redtail Technology, Inc. finds itself on the receiving end of a class action lawsuit. Filed by the attorneys at Blumenthal Nordrehaug Bhowmik De Blouw LLP, the suit hammers Redtail for allegedly failing to honor California's strict meal and rest period requirements, alongside other labor code...

UBCF & GGP Join Forces for Nationwide Pink Bag Drive

Caring Through Community: Pink Bag Events Unroll What do you get when compassion meets action? That's the story with the United Breast Cancer Foundation (UBCF) and GGP's Pink Bag Event. Here in 2026, these folks are doing something so damn important, you'd wonder why more don’t follow suit. For the fifth straight year, they're rolling out a campaign that bridges the gap...

HK Boosts Oversight of Building Repairs Post-Blaze

Big Moves After a Tragic Fire Hong Kong's revamping its approach to building maintenance and oversight, clearly in reaction to the horrific Wang Fuk Court blaze last year. That fire didn't just leave scars; it blew open glaring gaps in the city's oversight of building repairs. The government's now jumping into action by launching a raft of measures aimed at preventing...

Alignment Healthcare Faces Investigation Over Alleged Fraud

Rough Waters at Alignment Healthcare Not every day we hear about a company sinking its own ship over bookkeeping shenanigans, but here we are. Alignment Healthcare, sitting on Nasdaq under ticker ALHC, is facing the kind of scrutiny that sends shivers down a boardroom's spine. Yeah, Kahn Swick & Foti—those big hitters in securities litigation—have launched an...

NIDS Aims Global with CES 2027, Boosts Sensor Supply

Pushing Boundaries at CES 2027 Kicking into high gear, NIDS Co., Ltd. is eyeing the CES 2027 stage like it's their personal gold rush. Already a heavyweight in environmental sensors, the company is all set to seize fresh international opportunities and expand their B2B supply footprint worldwide. Already Turning Heads Founded back in 2000, NIDS ain't new to the sensor...